Health Care Delivery

Treatment with the interleukin-36 inhibitor spesolimab was associated with improved lesion clearance vs placebo after one week, but also a greater incidence of infection and systemic drug reactions.

At least 8 biosimilars were approved in Canada over the past 12 months, as policy makers made a strong push for biosimilar acceptance, which led to a change in prescribing patterns.

David Ramsey, MD, PhD, MPH, outlines what may have contributed to patients' decisions to return to in-person eye care following a telehealth appointment.

Analysis results revealed racial and sex disparities among patients with hypertrophic cardiomyopathy who receive implantable cardioverter-defibrillator (ICD) devices.

Findings of a post hoc analysis revealed a beneficial safety and efficacy profile for erenumab use among migraineurs with aura.

Anthony Fauci, MD, said the CDC is considering changes to its guidance requiring a negative COVID-19 test after 5-day quarantine; bipartisan legislation banning surprise medical billing goes into effect; booster vaccine programs may be limiting global vaccine supply for low- and middle-income countries.

Survival rates for patients with blast-phase chronic myeloid leukemia (BP-CML) are notoriously poor, necessitating effective treatments to fill the care gap for this group who often survive less than 1 year.

The most-read chronic obstructive pulmonary disease (COPD) articles of the year covered use of inhaled corticosteroids, palliative care for advanced COPD, and off-label prescribing of COPD therapies.

With a top treatment recommendation for obese women with polycystic ovary syndrome (PCOS) comprising lifestyle changes via diet changes and physical activity, this study’s investigators evaluated the effects of a ketogenic diet among this patient population.

This 8-part conversation with Blue Cross and Blue Shield of North Carolina and Newton Family Physicians, moderated by The American Journal of Managed Care® (AJMC®), focuses on the role of value-based care, independent care practices, and other aspects of health care that have been and continue to be affected by the continuing COVID-19 pandemic, even as we enter 2022. This is part 8.

This 8-part conversation with Blue Cross and Blue Shield of North Carolina and Newton Family Physicians, moderated by The American Journal of Managed Care® (AJMC®), focuses on the role of value-based care, independent care practices, and other aspects of health care that have been and continue to be affected by the continuing COVID-19 pandemic, even as we enter 2022. This is part 7.

This 8-part conversation with Blue Cross and Blue Shield of North Carolina and Newton Family Physicians, moderated by The American Journal of Managed Care® (AJMC®), focuses on the role of value-based care, independent care practices, and other aspects of health care that have been and continue to be affected by the continuing COVID-19 pandemic, even as we enter 2022. This is part 5.

This 8-part conversation with Blue Cross and Blue Shield of North Carolina and Newton Family Physicians, moderated by The American Journal of Managed Care® (AJMC®), focuses on the role of value-based care, independent care practices, and other aspects of health care that have been and continue to be affected by the continuing COVID-19 pandemic, even as we enter 2022. This is part 5.

This 8-part conversation with Blue Cross and Blue Shield of North Carolina and Newton Family Physicians, moderated by The American Journal of Managed Care® (AJMC®), focuses on the role of value-based care, independent care practices, and other aspects of health care that have been and continue to be affected by the continuing COVID-19 pandemic, even as we enter 2022. This is part 4.

This 8-part conversation with Blue Cross and Blue Shield of North Carolina and Newton Family Physicians, moderated by The American Journal of Managed Care® (AJMC®), focuses on the role of value-based care, independent care practices, and other aspects of health care that have been and continue to be affected by the continuing COVID-19 pandemic, even as we enter 2022. This is part 3.

This 8-part conversation with Blue Cross and Blue Shield of North Carolina and Newton Family Physicians, moderated by The American Journal of Managed Care® (AJMC®), focuses on the role of value-based care, independent care practices, and other aspects of health care that have been and continue to be affected by the continuing COVID-19 pandemic, even as we enter 2022. This is part 2.

This 8-part conversation with Blue Cross and Blue Shield of North Carolina and Newton Family Physicians, moderated by The American Journal of Managed Care® (AJMC®), focuses on the role of value-based care, independent care practices, and other aspects of health care that have been and continue to be affected by the continuing COVID-19 pandemic, even as we enter 2022. This is part 1.

The top 5 most-watched video interviews of 2021 on AJMC.com addressed myths about COVID-19 vaccination, eye health, and dermatologic conditions, as well as the use of sodium glucose co-transporter 2 (SGLT2) inhibitors in the treatment of type 2 diabetes, chronic kidney disease, and heart failure.

The top 5 most-read sleep articles of 2021 on AJMC.com covered emerging therapies in the treatment of obstructive sleep apnea and idiopathic hypersomnia, the effects of antidepressant use on rapid-eye movement sleep, and the sleep-related effects of COVID-19.

The new research is aimed at a patient group often left out of research studies.

Tech-driven connectivity and collaboration tools empower primary care providers (PCPs) to shepherd patient care, while simultaneously empowering patients to make more informed and strategic decisions about their own health and care journey.

David R. Stukus, MD, FACAAI, of Nationwide Children's Hospital and The Ohio State University College of Medicine, and a board member of the American College of Allergy, Asthma & Immunology, speaks on the lack of interventions to manage the underlying causes of exacerbation in atopic dermatitis.

Articles on treating and protecting patients with blood cancers from COVID-19 and the positive results of zanubrutinib to treat leukemia and lymphoma were among the most read of the year.

The new recommendations for systemic lupus erythematosus (SLE) use disease activity index scores and evaluator’s global assessment measures, but they do not include serology.

The most-read AJAC papers of 2021 analyze real-world programs to transform health care and provide insight into physician perspectives of health care and insurance.

An analysis uncovered racial, ethnic, and socioeconomic inequities regarding access to glucagon-like peptide-1 receptor agonists among US patients with diabetes.

This year's most-read inflammation articles included ones about Janus kinase inhibitors and the impact of biologics or systemic corticosteroids on severe COVID-19.

This year’s most-read articles on Fabry disease touched on advancements in therapy, health risks of the disease, and keys to improved diagnosis.

Data from the GLOW study of minimal residual disease evaluation following chemotherapy for chronic lymphocytic leukemia (CLL) show the kinase inhibitor/B-cell lymphoma-2 inhibitor pair produced superior outcomes compared with the alkylating agent/monoclonal antibody combination.

A study found significant differences in the therapeutic and diagnostic approaches to atopic dermatitis used by allergists, dermatologists, and pediatricians, and those recommended by guidelines.